| Title : Acetylcholinesterase Inhibitors in Myasthenic Crisis: A Systematic Review of Observational Studies - Prado_2021_Neurocrit.Care__1 |
| Author(s) : Prado MB, Jr. , Adiao KJ |
| Ref : Neurocrit Care , :1 , 2021 |
| Abstract : Current myasthenia gravis guidelines recommend intravenous immunoglobulin or plasmapheresis and discontinuation of pyridostigmine during myasthenic crisis. However, intravenous immunoglobulin or plasmapheresis is expensive and frequently not available in developing countries. This study aims to summarize the evidence of giving an acetylcholinesterase inhibitor in myasthenic crisis. Medline, Embase, and Cochrane databases and references were searched for observational studies that determined the use of acetylcholinesterase inhibitor in myasthenic crisis. The eligibility criteria were as follows: population, patients with myasthenic crisis, intervention (acetylcholinesterase inhibitor administration), and outcome (clinical improvement and complications). In total, 106 studies were identified, 92 through database searching (after removing duplicates) and 14 through other sources. Only eight were analyzed in the present systematic review. In five, acetylcholinesterase inhibitor was given at the start of the crisis, whereas in the other three, acetylcholinesterase inhibitor was discontinued initially and then restarted prior to extubation. Two observational analytic studies and three case reports showed improvement in different outcome measures. In the other three, improvement of outcome measures was also observed. Overall, a small proportion of patients developed cardiac arrhythmia and pneumonia after administration of acetylcholinesterase inhibitor alone, although this was not statistically different compared with those subjected to plasmapheresis. In summary, continuous intravenous infusion of pyridostigmine or neostigmine can be a substitute for intravenous immunoglobulin or plasmapheresis if these are not available during crisis; however, caution should be observed because of the aforementioned possible complications. |
| ESTHER : Prado_2021_Neurocrit.Care__1 |
| PubMedSearch : Prado_2021_Neurocrit.Care__1 |
| PubMedID: 34292475 |
Prado MB, Jr., Adiao KJ (2021)
Acetylcholinesterase Inhibitors in Myasthenic Crisis: A Systematic Review of Observational Studies
Neurocrit Care
:1
Prado MB, Jr., Adiao KJ (2021)
Neurocrit Care
:1